Exploring the Cardiovascular Impacts of Agmatine: A Systematic Review

Area of Science:

• Neuroscience
• Pharmacology
• Cardiovascular Research

Background:

• Agmatine (AG) is an endogenous neurotransmitter with diverse receptor interactions, including imidazoline and N-methyl-D-aspartate receptors.
• AG exhibits neuroprotective, anxiolytic, antidepressant, anticonvulsant, and anti-inflammatory properties.
• Cardiovascular effects of AG were investigated following the demonstration of clonidine's hypotensive effects.

Purpose of the Study:

• To systematically review and consolidate findings on agmatine's cardiovascular effects from preclinical studies.
• To understand the modulatory role of agmatine in cardiovascular function.

Main Methods:

• A systematic literature search was conducted across PubMed, Cochrane, and Embase databases.
• Keywords used included "agmatine" combined with "cardiac" or "vascular."
• Sixty preclinical studies were identified and included in the analysis.

Main Results:

• Agmatine, initially known as Clonidine Displacing Substance (CDS), demonstrated dose-dependent dual effects on cardiovascular parameters.
• Studies showed that AG can either increase or decrease blood pressure.
• AG also exhibited variable effects on heart rate, either increasing or decreasing it.

Conclusions:

• The cardiovascular effects of agmatine are complex and context-dependent.
• Dosage and route of administration significantly influence AG's impact on the cardiovascular system.
• The specific receptors targeted and the pathophysiological pathways involved dictate the observed cardiovascular outcomes of AG.